In another study, Tremelimumab, an immunoglobulin G2 (IgG2) monoclonal antibody that targets CTLA-4, was administered to 21 patients with HCV-associated HCC at around 15 mg/kg every three months until the tumor progressed. Here, CTLA4 is linked to hepatocellular carcinoma.